51 results about "Large cell lung cancer" patented technology

The invention discloses a (2-pyridylaldehyde)-2,6 pyridine diacylhydrazone copper compound and a preparation method.The copper compound has high anti-cancer activity and can be used as the raw material for preparing medicine for treating human breast cancer cells (MDA) and Human large cell lung cancer (NCI-H460).Compared with platinum anti-cancer medicine commonly used at present, the copper compound has the advantages of being high in anti-cancer activity, good in lipid solubility, low in cost, simple in preparation method and the like, and provides a new means for anti-cancer medicine development.

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues,and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide forapplication, and can be used for the clinical chemotherapy of the non-small cell lung cancer.

A method of treating large cell lung cancer in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a peptide comprising an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof, thereby treating the large cell lung cancer in the subject.

The invention relates to the nucleic acid and polypeptide sequences of two novel human GAK-related gene variants. The invention also relates to the process for producing the polypeptides of the variants. The invention further relates to the use of the nucleic acid and polypeptide sequences of the gene variants in diagnosing diseases associated with the deficiency of GAK gene, in particular, iron homeostasis impairment-related diseases or non-small cell lung cancer (NSCLC), e.g. large cell lung cancer.

The invention relates to a reagent kit for lung cancer detection. The reagent kit comprises a reagent for specific detection of miRNA (micro ribonucleic acid)-6070. The reagent kit can effectively detect a large cell lung cancer and quickly achieve quantitative detection of miRNA, and therefore achieves the purpose of quickly and effectively detecting the large cell lung cancer.

The invention discloses application of Lycojaponicumin A in preparation of medicaments for treating lung cancer. The compound shows good anti-lung cancer activity, can be used for preparing anti-lung cancer medicaments, and belongs to the technical field of new application of medicaments. The Lycojaponicumin A can prominently inhibit non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous cancer cells HTB-8 and human lung flat epithelial cancer cells QG-5 cultured in vitro, has a low inhibiting effect on human normal liver cells LO2 and peripheral blood lymphocytes, and shows obvious selectivity. The application of the Lycojaponicumin A in preparation of the medicaments for treating the lung cancer is made public for the first time; and because the skeleton type is completely novel, the Lycojaponicumin A has an unexpectedly strong lung cancer cell inhibiting activity.

The invention discloses an application of Lycojaponicumin C in the preparation of medicines for treating lung cancer. The compound shows good anti-lung cancer activity, can be used for the preparation of anti-lung cancer medicines and belongs to the technical field of new applications of medicines. The Lycojaponicumin C can be used for obviously inhibiting a non-small cell lung cancer cell A549, a large-cell lung cancer cell NCI-H460, a lung squamous carcinoma cell HTB-8 and a human lung epidermoid carcinoma cell QG-5 which are cultured in vitro, has a low inhibition effect on a human normal lung cell LO2 and a peripheral blood lymphocyte and shows up obvious selectivity. The application of the Lycojaponicumin C in the preparation of the medicines for treating the lung cancer is disclosed for the first time. As the skeleton type of the Lycojaponicumin C belongs to a brand-new skeleton type, the Lycojaponicumin C has unexpected strong inhibitory activity on the lung cancer cells.